ÂÜÀòÂÒÂ×

Dr. Mary Tagliaferri has a highly accomplished biotechnology career and is currently Executive Clinical Fellow and Senior Vice President of Nektar Therapeutics, where she also previously served as Chief Medical Officer. Nektar is a leading research-based biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need including treatments for cancer and auto-immune disease. At Nektar, Dr. Tagliaferri has been responsible for numerous clinical studies evaluating novel therapeutics in oncology and she was also instrumental in establishing key strategic partnerships. Previously, she served as Chief Medical Officer and Chief Regulatory Officer for Kanglaite-USA and was Co-Founder, President, and Board Member of Bionovo, Inc. Dr. Tagliaferri currently serves on the board of Enzo Biochem. She earned her Bachelor of Science degree at Cornell University and her medical degree at the University of California, San Francisco. Dr. Tagliaferri was named to the Women who Lead in Life Sciences and Most Influential Women in Business lists by the San Francisco Business Times in 2019 and was recognized as Woman of the Year, 2012, by the State of California, Assembly District 14. She has been the lead author or contributor to approximately 80 peer-reviewed journal publications.